Daewon Pharmaceutical Co., Ltd. (KRX:003220)
South Korea flag South Korea · Delayed Price · Currency is KRW
9,150.00
-160.00 (-1.72%)
Last updated: May 21, 2026, 2:14 PM KST

Daewon Pharmaceutical Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
196,330256,130305,427331,930393,197342,999
Market Cap Growth
-32.60%-16.14%-7.99%-15.58%14.64%-9.91%
Enterprise Value
330,549409,009434,054418,509453,068412,231
Last Close Price
9160.0011950.0013957.7515014.5517630.5814913.94
PE Ratio
--21.4913.8812.3149.08
Forward PE
12.089.779.779.779.779.77
PS Ratio
0.320.420.510.630.820.97
PB Ratio
0.720.931.071.261.581.57
P/TBV Ratio
0.861.121.271.371.741.77
P/FCF Ratio
15.6920.47-8.4121.3618.73
P/OCF Ratio
4.646.0510.176.4214.8915.30
PEG Ratio
-0.490.490.490.490.49
EV/Sales Ratio
0.550.680.730.790.951.16
EV/EBITDA Ratio
11.8415.029.288.407.2811.11
EV/EBIT Ratio
79.30117.3916.2712.9810.5621.36
EV/FCF Ratio
26.4232.69-10.6124.6222.52
Debt / Equity Ratio
0.740.740.660.550.470.57
Debt / EBITDA Ratio
7.427.424.002.931.873.34
Debt / FCF Ratio
16.1516.15-3.706.336.77
Net Debt / Equity Ratio
0.460.460.500.440.280.32
Net Debt / EBITDA Ratio
4.614.613.022.331.121.86
Net Debt / FCF Ratio
10.0410.04-29.222.943.783.78
Asset Turnover
1.011.011.101.101.090.93
Inventory Turnover
3.173.172.862.763.012.69
Quick Ratio
0.720.720.620.560.891.07
Current Ratio
1.191.191.191.151.621.77
Return on Equity (ROE)
-0.79%-0.79%3.68%9.15%13.13%3.07%
Return on Assets (ROA)
0.36%0.36%3.06%4.19%6.07%3.16%
Return on Invested Capital (ROIC)
-0.75%-0.73%4.14%8.38%11.21%2.75%
Return on Capital Employed (ROCE)
0.90%0.90%7.00%9.90%13.20%5.90%
Earnings Yield
-0.70%-0.54%4.65%7.21%8.12%2.04%
FCF Yield
6.37%4.88%-1.58%11.88%4.68%5.34%
Dividend Yield
2.60%2.09%---1.30%
Payout Ratio
--44.75%30.69%12.90%44.93%
Buyback Yield / Dilution
-0.67%-0.67%1.71%0.98%-3.09%0.58%
Total Shareholder Return
1.93%1.42%1.71%0.98%-3.09%1.88%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.